Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Abacavir & Didanosine-Important Safety Information from GlaxoSmithKline and Bristol-Myers Squibb as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
23/04/2008
Problem Or Issue:
Please find herewith an important safety communication from GlaxoSmithKline and Bristol-Myers Squibb on results pertaining to abacavir and didanosine
from the D:A:D Study (Data Collection of Advere effects of anti-HIV Drugs Study).
Abacavir sulfate -containing medicinal products (Ziagen Tablets and Oral Solution; Kivexa Tablets; Trizivir Tablets)
Didanosine -containing medicinal products (Videx Gastro-resistant capsules)
« Back
Date Printed: 04/05/2024